AIM ImmunoTech Inc. (NYSE American: AIM) announced results from a University of Pittsburgh Medical Center Phase 2 clinical trial evaluating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE